Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen Bos d 2 on specific T cells

International Immunology

Volumn 17, Issue 12, 2005, Pages 1573-1581

  Kinnunen, Tuure ^a   Kwok, William W ^b   Närvänen, Ale ^a   Rytkönen Nissinen, Marja ^a   Immonen, Anu ^a   Saarelainen, Soili ^a   Taivainen, Antti ^c   Virtanen, Tuomas ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Allergy; Immunotherapy; Peptide; T lymphocyte; Tetramer

Indexed keywords

ALLERGEN; BOS D 2 PEPTIDE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; LIPOCALIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL CLONE; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ALLERGENS; CYTOKINES; EPITOPES, T-LYMPHOCYTE; HETEROCYCLIC COMPOUNDS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYPERSENSITIVITY; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 28744448591     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxh332     Document Type: Article

References (58)

1. Kay, A. B. 2001. Allergy and allergic diseases: Parts I and II. N. Engl. J. Med. 344:30.
2. Bousquet, J., Lockey, R. and Malling, H. J. 1998. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102:558.
3. Larche, M. 2001. Inhibition of human T-cell responses by allergen peptides. Immunology 104:377.
4. Norman, P. S., Ohman, J. L., Jr, Long, A. A. et al. 1996. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154:1623.
5. Pene, J., Desroches, A., Paradis, L. et al. 1998. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J. Allergy Clin. Immunol. 102:571.
6. Oldfield, W. L., Larche, M. and Kay, A. B. 2002. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: A randomised controlled trial. Lancet 360:47.
7. Fellrath, J. M., Kettner, A., Dufour, N. et al. 2003. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trial. J. Allergy Clin. Immunol. 111:854.
8. Evavold, B. D., Sloan-Lancaster, J. and Allen, P. M. 1993. Tickling the TCR: Selective T-cell functions stimulated by altered peptide ligands. Immunol. Today 14:602.
9. Sloan-Lancaster, J. and Allen, P. M. 1996. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology. Annu. Rev Immunol. 14:1.
10. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. and Kuchroo, V. K. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3:397.
11. Brocke, S., Gijbels, K., Allegretta, M. et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379:343.
12. Alleva, D. G., Gaur, A., Jin, L. et al. 2002. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 51:2126.
13. Ercolini, A. M., Machiels, J. P., Chen, Y. C. et al. 2003. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/ neu-transgenic mice. J. Immunol. 170:4273.
14. Hartemann-Heurtier, A., Mars, L. T., Bercovici, N. et al. 2004. An altered self-peptide with superagonist activity blocks a CD8-mediated mouse model of Type 1 diabetes. J. Immunol. 172:915.
15. Fasler, S., Aversa, G., de Vries, J. E. and Yssel, H. 1998. Antagonistic peptides specifically inhibit proliferation, cytokine production, CD40L expression, and help for IgE synthesis by Der p 1-specific human T-cell clones. J. Allergy Clin. Immunol. 101:521.
16. Faith, A., Akdis, C. A., Akdis, M., Joss, A., Wymann, D. and Blaser, K. 1999. An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling. J. Immunol. 162:1836.
17. De Palma, R., Wu, S., Sallusto, F. et al. 1999. Use of antagonist peptides to inhibit in vitro T cell responses to Par j1, the major allergen of Parietaria judaica pollen. J. Immunol. 162:1982.
18. Janssen, E. M., van Oosterhout, A. J., van Rensen, A. J., van Eden, W., Nijkamp, F. P. and Wauben, M. H. 2000. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: Amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J. Immunol. 164:580.
19. Zeiler, T., Mantyjarvi, R., Rautiainen, J. et al. 1999. T cell epitopes of a lipocalin allergen colocalize with the conserved regions of the molecule. J. Immunol. 162:1415.
20. Kinnunen, T., Buhot, C., Narvanen, A. et al. 2003. The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. Eur. J. Immunol. 33:1717.
21. Novak, E. J., Liu, A. W., Nepom, G. T. and Kwok, W. W. 1999. MHC class II tetramers identify peptide-specific human CD4 (+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104:R63.
22. Holzer, U., Kwok, W. W., Nepom, G. T. and Buckner, J. H. 2003. Differential antigen sensitivity and costimulatory requirements in human Th1 and Th2 antigen-specific CD4+ cells with similar TCR avidity. J. Immunol. 170:1218.
23. Immonen, A., Saarelainen, S., Rautiainen, J. et al. 2003. Probing the mechanisms of low immunogenicity of a lipocalin allergen, Bos d 2, in a mouse model. Clin. Exp. Allergy 33:834.
24. Valitutti, S., Muller, S., Cella, M., Padovan, E. and Lanzavecchia, A. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148.
25. Bachmann, M. F., Oxenius, A., Speiser, D. E. et al. 1997. Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation. Eur. J. Immunol. 27:2195.
26. Caruso, A., Licenziati, S., Corulli, M. et al. 1997. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 27:71.
27. Savage, P. A., Boniface, J. J. and Davis, M. M. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10:485.
28. Reichstetter, S., Ettinger, R. A., Liu, A. W., Gebe, J. A., Nepom, G. T. and Kwok, W. W. 2000. Distinct T cell interactions with HLA class II tetramers characterize a spectrum of TCR affinities in the human antigen-specific T cell response. J. Immunol. 165:6994.
29. Santori, F. R., Holmberg, K., Ostrov, D., Gascoigne, N. R. and Vukmanovic, S. 2004. Distinct footprints of TCR engagement with highly homologous ligands. J. Immunol. 172:7466.
30. Rolland, J. and O'Hehir, R. 1998. Immunotherapy of allergy: Anergy, deletion, and immune deviation. Curr. Opin. Immunol. 10:640.
31. Anderton, S. M. 2001. Peptide-based immunotherapy of autoimmunity: A path of puzzles, paradoxes and possibilities. Immunology 104:367.
32. Vergelli, M., Hemmer, B., Kalbus, M. et al. 1997. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. J. Immunol. 158:3746.
33. Nicholson, L. B., Waldner, H., Carrizosa, A. M., Sette, A., Collins, M. and Kuchroo, V. K. 1998. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: Implications for autoimmunity. Proc. Natl Acad. Sci. USA 95:264.
34. Dressel, A., Chin, J. L., Sette, A., Gausling, R., Hollsberg, P. and Hafler, D. A. 1997. Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands. J. Immunol. 159:4943.
35. Tangri, S., Ishioka, G. Y., Huang, X. et al. 2001. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 194:833.
36. Hosken, N. A., Shibuya, K., Heath, A. W., Murphy, K. M. and O'Garra, A. 1995. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J. Exp. Med. 182:1579.
37. Rogers, P. R. and Croft, M. 1999. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance. J. Immunol. 163:1205.
38. Mishan-Eisenberg, G., Borovsky, Z., Weber, M. C., Gazit, R., Tykocinski, M. L. and Rachmilewitz, J. 2004. Differential regulation of TH1/TH2 cytokine responses by placental protein 14. J. Immunol. 173:5524.
39. Pfeiffer, C., Stein, J., Southwood, S., Ketelaar, H., Sette, A. and Bottomly, K. 1995. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J. Exp. Med. 181:1569.
40. Brogdon, J. L., Leitenberg, D. and Bottomly, K. 2002. The potency of TCR signaling differentially regulates NFATc/p activity and early IL-4 transcription in naive CD4+ T cells. J. Immunol. 168:3825.
41. Carballido, J. M., Carballido-Perrig, N., Terres, G., Heusser, C. H. and Blaser, K. 1992. Bee venom phospholipase A2-specific T cell clones from human allergic and non-allergic individuals: Cytokine patterns change in response to the antigen concentration. Eur. J. Immunol. 22:1357.
42. Carballido, J. M., Faith, A., Carballido-Perrig, N. and Blaser, K. 1997. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific T helper cells. Eur. J. Immunol. 27:515.
43. Jutel, M., Pichler, W. J., Skrbic, D., Urwyler, A., Dahinden, C. and Muller, U. R. 1995. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154:4187.
44. Bellinghausen, I., Metz, G., Enk, A. H., Christmann, S., Knop, J. and Saloga, J. 1997. Insect venom immunotherapy induces interleukin-10 production and a Th2- to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. 27:1131.
45. Ebner, C., Siemann, U., Bohle, B. et al. 1997. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 27:1007.
46. Suzuki, G., Kawase, Y., Koyasu, S., Yahara, I., Kobayashi, Y. and Schwartz, R. H. 1988. Antigen-induced suppression of the proliferative response of T cell clones. J. Immunol. 140:1359.
47. Critchfield, J. M., Racke, M. K., Zuniga-Pflucker, J. C. et al. 1994. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263:1139.
48. Critchfield, J. M., Zuniga-Pflucker, J. C. and Lenardo, M. J. 1995. Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. Cell. Immunol. 160:71.
49. Liblau, R. S., Tisch, R., Shokat, K. et al. 1996. Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Proc. Natl Acad. Sci. USA 93:3031.
50. Gardner, L. M., O'Hehir, R. E. and Rolland, J. M. 2004. High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-gamma+ T Cells, apoptosis of CD4+ IL-4+ T cells and T cell anergy. Int. Arch. Allergy Immunol. 133:1.
51. Mallone, R., Kochik, S. A., Laughlin, E. M. et al. 2004. Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells. Diabetes 53:971.
52. Viola, A. and Lanzavecchia, A. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104.
53. Falk, K., Rotzschke, O. and Strominger, J. L. 2000. Antigen-specific elimination of T cells induced by oligomerized hemagglutinin (HA) 306-318. Eur. J. Immunol. 30:3012.
54. Kwok, W. W., Liu, A. W., Novak, E. J. et al. 2000. HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: Direct detection of immunodominant antigen-responsive cells. J. Immunol. 164:4244.
55. Meyer, A. L., Trollmo, C., Crawford, F. et al. 2000. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc. Natl Acad. Sci. USA 97:11433.
56. Kotzin, B. L., Falta, M. T., Crawford, F. et al. 2000. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc. Natl Acad. Sci. USA 97:291.
57. Quarsten, H., McAdam, S. N., Jensen, T. et al. 2001. Staining of celiac disease-relevant T cells by peptide-DQ2 multimers. J. Immunol. 167:4861.
58. Reijonen, H., Novak, E. J., Kochik, S. et al. 2002. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 51:1375.